Suspension of trading
Valuation Exscientia plc
Stocks
EXAI
US30223G1022
Biotechnology & Medical Research
Company Valuation: Exscientia plc
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 |
|---|---|---|---|
| Market Cap 1 | 1,757 | 543.6 | 628.7 |
| Change | - | -69.06% | 15.67% |
| Enterprise Value (EV) 1 | 1,200 | 51.65 | 284.6 |
| Change | - | -95.69% | 451% |
| P/E | -14.8x | -4.55x | -4.28x |
| PBR | 3.11x | 1.14x | 1.78x |
| PEG | -0x | 3.03x | -0.2x |
| Capitalization / Revenue | 64.2x | 20x | 31.3x |
| EV / Revenue | 43.9x | 1.9x | 14.2x |
| EV / EBITDA | -23.4x | -0.32x | -1.75x |
| EV / EBIT | -22x | -0.31x | -1.63x |
| EV / FCF | - | - | - |
| FCF Yield | - | - | - |
| Dividend per Share 2 | - | - | - |
| Rate of return | - | - | - |
| EPS 2 | -0.9871 | -0.9722 | -1.175 |
| Distribution rate | - | - | - |
| Net sales 1 | 27.36 | 27.22 | 20.08 |
| EBITDA 1 | -51.31 | -159.9 | -162.5 |
| EBIT 1 | -54.64 | -167.6 | -174.5 |
| Net income 1 | -49.23 | -118.7 | -146 |
| Net Debt 1 | -557 | -491.9 | -344.1 |
| Reference price 2 | 14.593 | 4.424 | 5.032 |
| Nbr of stocks (in thousands) | 1,20,388 | 1,22,878 | 1,24,940 |
| Announcement Date | 23/03/22 | 23/03/23 | 21/03/24 |
1GBP in Million2GBP
Estimates
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | - | - | - | - | 63Cr | |
| 33.31x | 5.98x | 17.9x | 0.97% | 4.8TCr | |
| 35.42x | 3.39x | 14.64x | -.--% | 4.53TCr | |
| 47.15x | 5.46x | 29.88x | -.--% | 4.09TCr | |
| -20.54x | 221.64x | -22.17x | -.--% | 4.28TCr | |
| 26.85x | 7.74x | 19.93x | 0.42% | 2.96TCr | |
| 35.29x | 5.79x | 26.32x | -.--% | 1.73TCr | |
| 25.91x | 2.22x | 9.63x | 1.03% | 1.53TCr | |
| -59.05x | 9.67x | 236.13x | -.--% | 1.48TCr | |
| Average | 15.54x | 32.74x | 41.53x | 0.3% | 2.83TCr | |
| Weighted average by Cap. | 20.38x | 41.97x | 25.55x | 0.3% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
